vmd-928
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2018 (NCT03556228)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Appendiceal Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Adenoid Cystic · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colonic Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Esthesioneuroblastoma, Olfactory · Phase 1
- Gallbladder Neoplasms · Phase 1
- Leiomyosarcoma · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Thymoma · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
- Uterine Neoplasms · Phase 1
Mechanism of action
- Nerve growth factor receptor Trk-AALLOSTERIC ANTAGONIST
NTRK1 allosteric antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03556228 | Phase 1 | Jun 8, 2018 | MedAssessment, VM Oncology, LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedAssessment | For profit | 1 | 0 | 1 | 2018 |
| VM Oncology, LLC | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1